MGNX News and Press, MacroGenics Inc. From 12/16/20

MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® ( trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial MARGENZA is approved, in combination with che...

Gainers: [[SCPS]] +27.7%. [[EOLS]] +23.2%. [[GTAT]] +21.8%. [[MGNX]] +15.7%. [[SELB]] +10.3%.Losers: [[SCYX]] -15.8%. [[QTT]] -9.2%. [[APEN]] -6.8%. [[TRITW]] -6.7%. [[ETM]] -4.3%. For further details see: SCPS, EOLS, SCYX and QTT among after-hours movers

The FDA has approved MacroGenics' (MGNX) Margenza (margetuximab-cmkb), in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens,Matgenza is the first product approved from Macr...

MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® ( trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial MARGENZA is approved, in combination wi...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe earnings calendar is almost bare in the week ahead, although reports from FedEx (NYSE:FDX) and Nike (NYSE:NKE) could ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

53.8% ORR in relapsed/refractory DLBCL patients  Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date  ROCKVILLE, MD, Dec. 07, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: M...

31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patients Median duration of response = 8.13 months ROCKVILLE, MD, Dec. 06, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on disco...

MacroGenics accesses EVERSANA’s full suite of commercial services for which both parties share expenses EVERSANA may earn revenue share payments over five years subject to predefined cap MacroGenics’ projected cash runway remains into 2023 ROCK...

MacroGenics (MGNX) has received $25M in milestone payment from Incyte (INCY), related to retifanlimab, an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte (as INCMGA0012). The payment was triggered by recent initiation of POD1UM-303, ...